Taken together, these results place EGFR as a mediator of ETV1 oncogenic activity both in early and advanced prostate carcinogenesis, while ERG overexpression seems to indirectly repress EGFR activation in early PCa carcinogenesis. This evidence concerns the gene ERG and medical procedure.